Kirt Poss is a Senior Commercialization Advisor with NobleReach Foundation and brings more than 25 years of executive leadership to the company.

Prior to this role, he was CEO-US of ProtaGene, a provider of advanced analytics solutions for biopharmaceutical and gene therapy platform development. He also served as President and CEO of BioAnalytix, where he led the company from early commercialization through two successful M&As, including with Protagen Protein Services in 2019, and then with a private equity firm to create ProtaGene in 2021. Mr. Poss also served as President and CEO of VisEn Medical, a biomarker imaging company that he co-founded and guided from its formation in 2000 through product development, worldwide commercialization, pharmaceutical partnerships, and M&A with PerkinElmer in 2010.

Earlier in his career, Mr. Poss worked in healthcare business strategy consulting with Kendall Strategies and in scientific research at the Center for Molecular Imaging Research at the Massachusetts General Hospital and Harvard Medical School. He is a coauthor of several scientific publications and multiple patents in biomarker imaging and pharmaceutical development.